Quest Diagnostics (NYSE: DGX), a Seaucus, NJ-based provider of diagnostic information services, acquired Haystack Oncology, a Baltimore, MD-based early-stage oncology company.
Under the terms of the agreement, Quest will pay $300 million in cash at closing, net of cash acquired, and up to an additional $150 million on achieving future performance milestones. The company expects the acquisition to be modestly dilutive to earnings over the next three years and accretive by 2026. The transaction is expected to be completed in the second quarter, subject to customary regulatory review. The acquisition will leverage Quest’s expertise and scale in oncology, genomics and pathology. Quest employs approximately 400 pathologists through its AmeriPath specialty pathology-diagnostics business and provides approximately 7,000 patient access points in the United States for blood and other specimen collection. In addition, Quest’s expertise in next-generation tumor sequencing includes being able to identify patient-specific mutations for Haystack’s tumor-informed MRD approach. Quest also serves a broad swath of providers and connects with nearly 850 electronic health records systems, supporting convenient electronic longitudinal MRD reporting.
Led by Dan Edelstein, CEO and President, Haystack Oncology uses the ctDNA detection technology to see the levels of ctDNA in blood to report residual, recurrent, or resistant disease earlier and deliver the right treatment to the right person at the right time.
Following the close of the acquisition, Quest expects to adapt the MRD test developed at Haystack as the basis for new clinical lab services available beginning in 2024. Development efforts will focus initially on MRD tests for colorectal, breast and lung cancers.
FinSMEs
28/04/2023